Form 4: Atai Life Sciences Director Amir H. Kalali Acquires 103,000 Stock Options
SEC Form 4 Filing
Director Amir H. Kalali acquired 103,000 stock options in Atai Life Sciences N.V. on June 13, 2024.
Summary
- Amir H. Kalali, a director of ATAI Life Sciences N.V., acquired 103,000 stock options on June 13, 2024.
- The stock options have an exercise price of $1.34.
- The options vest on the earlier of the day before ATAI Life Sciences N.V.'s next annual meeting or June 13, 2025.
- The options expire on June 13, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing the acquisition of stock options by a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could be seen as a positive sign by shareholders, indicating confidence in the company's future performance.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Date of earliest transaction: Amir H. Kalali acquired 103,000 stock options. |
| 06/13/2024 | Stock option grant date. |
| 06/13/2025 | Stock options vest on the earlier of the day before the next annual meeting or this date. |
| 06/13/2034 | Stock options expiration date. |
| 06/14/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.